Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of MLN8237 in adult patients with acute myelogenous leukemia and high-grade myelodysplastic syndrome
2008-006977-34Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alisertib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Millennium Pharmaceuticals. Primary endpoint: Response rate (PR + CR). Started Mar 2009; status: completed.
02
Drugs
alisertib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2008-006977-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006977-34.